Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis

Institut National de la Santé Et de la Recherche Médicale, France96,883 enrolled

Overview

This study aims to quantify and follow the cumulative incidence of SARS-CoV-2 infection in the French population using serological tests and to assess the determinants of infection from Constances, E3N-E4N, ELFE-Epipage 2 and NutriNet-Santé cohorts.

The primary objective is to assess the cumulative incidence of infection in the general population using dried blood spot sampling. The secondary objectives are: * To identify factors associated with a positive SARS-CoV-2 infection (positive serology) and to characterize the durability of the serological response to SARS-CoV-2 * To identify associations of symptoms predictive of a SARS-CoV-2 infection * To estimate the health care use associated with a SARS-CoV-2 infection * To estimate the fraction of sub-clinical infections or infections not captured by the healthcare system; * To study the acceptability of a mass anti-SARS-CoV-2 serological testing and the impact of its result, linked with social inequalities in health; * To estimate the individual and collective impact of containment and other preventive measures on the risk of SARS-CoV-2 infection; * To study the impact of social and territorial inequalities on seroprevalence levels.

Study Type

OBSERVATIONAL

Enrollment

96,883

Conditions

SARS-CoV 2

Interventions

Non applicableBIOLOGICAL

to collect data from questionnaires and to collect serological samples

Eligibility

Sex: ALLHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * non applicable, already enrolled in the cohorts Exclusion Criteria: * non applicable

Locations (1)

Inserm

Paris, France

Outcomes

Primary Outcomes

Cumulative incidence of SARS-Cov2 infection in the general population.

Simple and corrected estimate of the number of seropositive individuals/number of individuals at risk in different strata, based on weighting and calibration and taking into account the random cohort effect.

Time frame: 8 months

Secondary Outcomes

Maintenance over time of the acquisition of anti-SARS-Cov2 antibodies

Decay kinetics estimated by mixed effect model with repeated data per subject

Time frame: 8 months

Rate of use of care (medical care, hospitalization, center 15) linked to the occurrence of symptoms suggestive of a SARS-Cov2 infection, and share attributable to the infection

Rate of use of care (medical care, hospitalization, center 15) linked to the occurrence of symptoms suggestive of a SARS-Cov2 infection, and share attributable to the infection during a time frame of 8 months

Time frame: 8 months

Proportion of infections without reported or pauci-symptomatic symptoms and their epidemiological and social determinants

Proportion of infections without reported or pauci-symptomatic symptoms and their epidemiological and social déterminants during a time frame of 8 months.

Time frame: 8 months

Proportion of tests proposed, accepted, performed, based on social and demographic characteristics

Proportion of tests proposed, accepted, performed, based on social and demographic characteristics during a time frame of 8 months.

Time frame: 8 months

Proportion and intensity of use of barrier measures (hydroalcoholic gel, mask, social distancing, description of outings / reasons, duration, frequency) and association with the level of seroprevalence

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.